Payment overview · 2025
General Payments
$381.18
21 reported records · 4 companies
Healthcare provider profile · identity verified
Scott O Caudle, MD
Allopathic & Osteopathic Physicians|Surgery · ELIZABETHTON, TN · NPI 1770570772
Verified facts
What the public records show
CMS Open Payments records show Scott O Caudle, MD received $381.18 in general payments during 2025 across 21 reported records.
ABBVIE INC. accounted for 71.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Vraylar by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $272.08 | 71.4% | 17 | 2025 |
| REVANCE THERAPEUTICS, INC. | Unresolved — no canonical attribution shown | $80.98 | 21.2% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.09 | 3.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.03 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $381.18 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $222.80 | 11 | 2025 |
Source payment records
|
|||||
| DAXXIFY Normalized: daxxify |
Drug | REVANCE THERAPEUTICS, INC. | $80.98 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $44.54 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.09 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 58 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 58 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
128 | 34 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 520 | 127 |
| Gabapentin | Gabapentin | 477 | 69 |
| Omeprazole | Omeprazole | 378 | 91 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 376 | 24 |
| Promethazine Hcl | Promethazine Hcl | 324 | 68 |
| Lisinopril | Lisinopril | 323 | 82 |
| Tizanidine Hcl | Tizanidine Hcl | 274 | 56 |
| Furosemide | Furosemide | 264 | 67 |
| Atorvastatin Calcium | Atorvastatin Calcium | 243 | 59 |
| Ibuprofen | Ibuprofen | 238 | 49 |
| Carvedilol | Carvedilol | 195 | 47 |
| Levothyroxine Sodium | Levothyroxine Sodium | 194 | 46 |
| Quetiapine Fumarate | Quetiapine Fumarate | 183 | 34 |
| Ozempic | Semaglutide | 172 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 171 | 38 |
| Potassium Chloride | Potassium Chloride | 152 | 29 |
| Pregabalin | Pregabalin | 152 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 150 | 35 |
| Azithromycin | Azithromycin | 141 | 79 |
| Ondansetron Hcl | Ondansetron Hcl | 133 | 43 |
| Buspirone Hcl | Buspirone Hcl | 132 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 129 | 30 |
| Linzess | Linaclotide | 128 | 34 |
| Metformin Hcl Er | Metformin Hcl | 127 | 26 |
| Testosterone Cypionate | Testosterone Cypionate | 122 | 27 |
| Levofloxacin | Levofloxacin | 119 | 58 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 116 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 116 | 24 |
| Montelukast Sodium | Montelukast Sodium | 116 | 31 |
| Meloxicam | Meloxicam | 114 | 25 |
| Prednisone | Prednisone | 108 | 43 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 96 | 23 |
| Rizatriptan | Rizatriptan Benzoate | 95 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 93 | 24 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 92 | 43 |
| Methylprednisolone | Methylprednisolone | 91 | 62 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 90 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 27 |
| Sertraline Hcl | Sertraline Hcl | 84 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 84 | 22 |
| Amlodipine Besylate | Amlodipine Besylate | 83 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 83 | suppressed |
| Estradiol | Estradiol | 82 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 77 | 19 |
| Simvastatin | Simvastatin | 75 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 75 | 27 |
| Clonidine Hcl | Clonidine Hcl | 74 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 71 | 22 |
| Topiramate | Topiramate | 71 | 14 |
| Allopurinol | Allopurinol | 69 | 13 |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 69 | suppressed |
| Bupropion Xl | Bupropion Hcl | 68 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 19 |
| Progesterone | Progesterone, Micronized | 67 | 14 |
| Trazodone Hcl | Trazodone Hcl | 67 | 22 |
| Famotidine | Famotidine | 66 | 20 |
| Losartan Potassium | Losartan Potassium | 66 | 19 |
| Trulicity | Dulaglutide | 65 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 64 | 18 |
| Baclofen | Baclofen | 60 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 59 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 58 | 32 |
| Rexulti | Brexpiprazole | 58 | suppressed |
| Vraylar | Cariprazine Hcl | 58 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 56 | 20 |
| Donepezil Hcl | Donepezil Hcl | 55 | 17 |
| Mupirocin | Mupirocin | 55 | 25 |
| Alendronate Sodium | Alendronate Sodium | 54 | 14 |
| Methocarbamol | Methocarbamol | 53 | suppressed |
| Metformin Hcl | Metformin Hcl | 50 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 49 | suppressed |
| Risperidone | Risperidone | 49 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | 13 |
| Spiriva Respimat | Tiotropium Bromide | 46 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 44 | suppressed |
| Entresto | Sacubitril/Valsartan | 43 | suppressed |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Eliquis | Apixaban | 39 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | suppressed |
| Amoxicillin | Amoxicillin | 38 | 24 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 38 | 11 |
| Fluconazole | Fluconazole | 37 | 21 |
| Celecoxib | Celecoxib | 36 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | suppressed |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | 13 |
| Atenolol | Atenolol | 32 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 32 | 18 |
| Jardiance | Empagliflozin | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 17 |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Lidocaine | Lidocaine | 28 | suppressed |
| Humalog | Insulin Lispro | 27 | suppressed |
| Nitroglycerin | Nitroglycerin | 27 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 27 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 24 | suppressed |
| Nystatin | Nystatin | 24 | 15 |
| Atomoxetine Hcl | Atomoxetine Hcl | 22 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 12 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Humira(Cf) Pen | Adalimumab | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Ubrelvy | Ubrogepant | 17 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Armour Thyroid | Thyroid,pork | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $381.18 · 21 records | ABBVIE INC. | BOTOX, CAPLYTA, DAXXIFY, REXULTI, VRAYLAR | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error